Bodenstedt Matthias's most recent trade in MoonLake Immunotherapeutics - Ordinary Shares - Class A was a trade of 354,296 Class A ordinary shares, par value $0.0001 per share done . Disclosure was reported to the exchange on Jan. 7, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| MoonLake Immunotherapeutics (Class A) | Matthias Bodenstedt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 354,296 | 1,276,305 | - | 0 | Class A ordinary shares, par value $0.0001 per share | |
| MoonLake Immunotherapeutics (Class A) | Matthias Bodenstedt | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Dec 2025 | 294,473 | 0 | - | - | Class C ordinary shares, par value $0.0001 per share | |
| MoonLake Immunotherapeutics (Class A) | Matthias Bodenstedt | Chief Financial Officer | 19 Dec 2025 | 294,473 | 922,009 | - | - | Class A ordinary shares, par value $0.0001 per share | ||
| MoonLake Immunotherapeutics (Class A) | Matthias Bodenstedt | Chief Financial Officer | 19 Dec 2025 | 8,754 | 0 | - | - | Common shares, par value CHF 0.10 per share, of MoonLake AG | ||
| MoonLake Immunotherapeutics (Class A) | Matthias Bodenstedt | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 9.09 per share. | 08 Oct 2025 | 10,870 | 627,536 | - | 9.1 | 98,808 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Matthias Bodenstedt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 95,763 | 616,666 | - | 0 | Class A ordinary shares, par value $0.0001 per share | |
| MoonLake Immunotherapeutics (Class A) | Bodenstedt Matthias | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 59.22 per share. | 19 Dec 2023 | 94,736 | 526,167 | - | 59.2 | 5,610,266 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Matthias Bodenstedt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 58.34 per share. | 19 Dec 2023 | 5,264 | 520,903 | - | 58.3 | 307,102 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Matthias Bodenstedt | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2023 | 410,796 | 0 | - | - | Class C ordinary shares, par value $0.0001 per share | |
| MoonLake Immunotherapeutics (Class A) | Matthias Bodenstedt | Chief Financial Officer | 05 Apr 2023 | 410,796 | 410,796 | - | - | Class A ordinary shares, par value $0.0001 per share | ||
| MoonLake Immunotherapeutics (Class A) | Matthias Bodenstedt | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2023 | 147,135 | 357,445 | - | - | Class C ordinary shares, par value $0.0001 per share | |
| MoonLake Immunotherapeutics (Class A) | Matthias Bodenstedt | Chief Financial Officer | 05 Apr 2023 | 147,135 | 557,931 | - | - | Class A ordinary shares, par value $0.0001 per share | ||
| MoonLake Immunotherapeutics (Class A) | Matthias Bodenstedt | Chief Financial Officer | 05 Apr 2023 | 12,212 | 0 | - | - | Common shares, par value CHF 0.10 per share, of MoonLake AG | ||
| MoonLake Immunotherapeutics (Class A) | Matthias Bodenstedt | Chief Financial Officer | 05 Apr 2023 | 4,374 | 10,626 | - | - | Common shares, par value CHF 0.10 per share, of MoonLake AG |